Advertisement
U.S. markets close in 10 minutes
Advertisement

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
10.950.00 (0.00%)
As of 10:32AM EST. Market open.
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in USD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 12/4/2023
Current
Market Cap (intraday)
141.06M
Enterprise Value
129.96M
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
11.73
Enterprise Value/Revenue
N/A
Enterprise Value/EBITDA
-23.61

Trading Information

Stock Price History

Beta (5Y Monthly) -0.03
52-Week Change 3-63.77%
S&P500 52-Week Change 314.90%
52 Week High 332.89
52 Week Low 310.70
50-Day Moving Average 314.83
200-Day Moving Average 320.45

Share Statistics

Avg Vol (3 month) 31.89k
Avg Vol (10 day) 33.7k
Shares Outstanding 513.01M
Implied Shares Outstanding 613.01M
Float 81.46M
% Held by Insiders 188.76%
% Held by Institutions 10.01%
Shares Short (Nov 14, 2023) 42.12k
Short Ratio (Nov 14, 2023) 41.36
Short % of Float (Nov 14, 2023) 40.09%
Short % of Shares Outstanding (Nov 14, 2023) 40.02%
Shares Short (prior month Oct 12, 2023) 4442

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2023
Most Recent Quarter (mrq)Jun 29, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-25.59%
Return on Equity (ttm)-41.71%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -5.98M
Net Income Avi to Common (ttm)-5.87M
Diluted EPS (ttm)-0.45
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)11.56M
Total Cash Per Share (mrq)0.89
Total Debt (mrq)463.67k
Total Debt/Equity (mrq)3.87%
Current Ratio (mrq)19.15
Book Value Per Share (mrq)0.92

Cash Flow Statement

Operating Cash Flow (ttm)-4.96M
Levered Free Cash Flow (ttm)-2.28M